Showing results (81-90 of 190) with videos related to

Sort By:
Pageof 19
Proteomics|July 20, 2017
Proteomic Analysis of Neuroblastoma-Derived Exosomes: New Insights into a Metastatic SignatureMarta Colletti, Andrea Petretto, Angela Galardi, et al.
Sarcoma|December 11, 2012
Bone sarcomas: from biology to targeted therapiesNathalie Gaspar, Angela Di Giannatale, Birgit Geoerger, et al.
Nature Cancer|April 10, 2023
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumabArash Nabbi, Arnavaz Danesh, Osvaldo Espin-Garcia, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) ConsortiumUri Ilan, Alba Rubio-San-Simón, Natasha van Eijkelenburg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2024
METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumorsNicolas André, Marie Cécile Le Deley, Clémence Léguillette, et al.
Neuron|January 6, 2022
Local feedback inhibition tightly controls rapid formation of hippocampal place fieldsSebi V Rolotti, Mohsin S Ahmed, Miklos Szoboszlay, et al.
Nature Reviews. Clinical Oncology|May 17, 2017
Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspectiveLucas Moreno, Andrew D J Pearson, Xavier Paoletti, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2018
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'Patrick Schöffski, Agnieszka Wozniak, Michael G Leahy, et al.
Pediatric Blood & Cancer|August 25, 2016
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trialsLucas Moreno, Herve Rubie, Amalia Varo, et al.
The Lancet. Oncology|November 30, 2019
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 studyBirgit Geoerger, C Michel Zwaan, Lynley V Marshall, et al.
Pageof 19